The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
Krilov
Leonard R
LR
Pediatric Infectious Disease, Department of Pediatrics, Winthrop University Hospital, Mineola, New York 11501, USA. lkrilov@winthrop.org
Weiner
Leonard B
LB
Yogev
Ram
R
Fergie
Jaime
J
Katz
Ben Z
BZ
Henrickson
Kelly J
KJ
Welliver
Robert C
RC
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine; D005865:Gestational Age; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000191:economics / Q000517:prevention & control*; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D018357:Respiratory Syncytial Virus Infections / Q000191:economics / Q000517:prevention & control*; D018570:Risk Assessment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab